| 2022 EFPIA DISCLOSURE (inc. Vaccines Europe) |   |  |  |  |                        |   |  |                          |  |  |   |     |  |
|--|---|--|--|--|------------------------|---|--|--------------------------|--|--|---|-----|--|
|  | 2022 FFFF DISCLOSURE (III., VACUINES CUIDPE) Date of publication: 3016 f June 2023  |  |  |  |                        |   |  |                          |  |  |   |     |  |
|  | Full Name   |  |  |  |                        |   | Contribution to costs of Events  |                          |  | Fee for service and consultancy                  |   |     |  |
|  |   |  |  |  |                        | Donations and Grants to<br>HCOs and POs | Sponsorship<br>agreements with<br>HCOs / third parties<br>appointed by HCOs<br>to<br>manage an Event | Registration Fees        | Travel &<br>Accommodation                        | Fees excl. VAT                                   | Related expenses<br>agreed in the fee for<br>service or consultancy<br>contract, including travel<br>&<br>accommodation |     |  |
|  | INDIVIDUAL NAMED DISCLOSURE   | - one line per HCP (i.e. al                            | I transfers of value during                            | a year for an individual HCP will be summed up: it | temization should be a | vailable for the individual R           | Recipient or public auth   | orities' consultation on | y, as  |  |   |     |  |
|  | Inger Marie Løes  | HUS  | Norway   | Haukeland University Hospital, Bergen              |                        | N/A                                     | N/A  |                          |  | 15.000   |   |     |  |
|  |   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   | _   |  |
|  |   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   | _   |  |
|  |   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   |     |  |
|  |   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   |     |  |
| HCPs   |   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   | l   |  |
| Ŧ  |   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   |     |  |
|  |   |  |  | OTHER, NOT INCLUDED ABOVE - w                      | here information can   | ot be diclsoed on an indiv.             | idual basis for legal rec  | sons                     |  |  |   |     |  |
|  | Aggregate amount attributable to transfers of value to such Recipients  |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   |     |  |
|  | Number of Recipients in aggregate disclosure  |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   | •   |  |
|  | You fit in number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients   |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   | t   |  |
|  | disclosed   |  |  |  |                        | ,                                       |  |                          |  |  |   |     |  |
|  |   |  |  |  |                        |   |  |                          |  |  |   |     |  |
|  | NONIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as            |  |  |  |                        |   |  |                          |  |  |   |     |  |
|  |   |  |  | 5 - / /  |                        | 1                                       |  |                          | T  | T  | 1   |     |  |
|  |   |  |  |  |                        |   |  |                          |  |  |   | İ   |  |
|  |   |  |  |  |                        |   |  |                          |  |  |   | 1   |  |
| HCOs   | OTHER, NOT INCLUDED ABOVE - where information cannot be dictated on an individual basis for legal reasons   |  |  |  |                        |   |  |                          |  |  |   |     |  |
| £  | Aggregate amount attributable to transfers of value to such Recipients  |  |  |  |                        | N/A                                     | N/A  | isons                    | 1  | 1  | 1   |     |  |
|  | Number of Recipients in aggregate disclosure  |  |  |  |                        | N/A                                     | N/A  |                          |  |  |   | +   |  |
|  | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients   |  |  |  |                        | N/A<br>N/A                              | N/A<br>N/A   |                          | <b> </b>   | <b> </b>   | 1   | 1   |  |
|  | disclosed   |  |  |  |                        | N/A                                     | NA   |                          |  |  |   |     |  |
|  |   |  |  |  |                        |   |  |                          |  |  |   |     |  |
|  | MOVIDUAL NAMED DISCLOSURE - one line per PO (i.e. all transfers of value during a year for an individual PO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) |  |  |  |                        |   |  |                          |  |  |   |     |  |
|  | Norsk Gastrointestinal Cancer Gruppe  | Grant to support the meeting the 28-29th of April 2022 |  |  |                        | 30.000 NOK<br>18.000 NOK                |  |                          |  |  |   |     |  |
|  | Onkologisk Forum Norge  | Grant to support the mee                               | nt to support the meeting the 17-18th of November 2022 |  |                        |   |  |                          |  |  |   | J   |  |
|  |   |  |  | <u> </u>   |                        |   |  |                          |  |  | ļ   |     |  |
| POs  | OTHER, NOT INCLUDED ABOVE - where information cannot be dichoed on an individual basis for legal reasons  |  |  |  |                        |   |  |                          |  |  |   |     |  |
| ۵.   | Aggregate amount attributable to transfers of value to such Recipients  |  |  |  |                        |   |  | Sons-                    | 1  | 1  |   |     |  |
|  | Number of Recipients in aggregate disclosure  |  |  |  |                        |   | N/A<br>N/A   |                          | <del>                                     </del> | <del>                                     </del> | 1   | 1   |  |
|  | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients   |  |  |  |                        |   | N/A  |                          |  |  |   | +   |  |
|  | is of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed  |  |  |  |                        |   | N/A  |                          |  |  |   |     |  |
|  |   |  |  |  |                        |   | •  | •                        | •  |  | •   |     |  |
|  |   | AGGREGATE DISCLOSURE                                   |  |  |                        |   |  |                          |  |  |   |     |  |
|  | Transfers of Value re Research & Development as defined N   |  |  |  |                        |   |  |                          |  |  |   | N/A |  |